Mentioned:
Compass Pathways wants to bring psilocybin to veterans in America. Which is exactly why they’re partnering up with the United States Department of Veterans Affairs.
What’s happening:
- Compass Pathways (NASDAQ: CMPS) has partnered with the United States Department of Veterans Affairs on a multi-site randomized controlled clinical trial to evaluate the safety of psilocybin in treatment-resistant depression in veterans
Why it matters:
- The new study is aiming to evaluate the efficacy and safety of Compass Pathways’ proprietary COMP360 synthetic psilocybin drug to treat treatment-resistant depression in veterans, including those with co-occurring PTSD
Going deeper:
- This is the first time ever that Compass Pathways and the United States Department of Veterans Affairs have partnered on a multi-site, randomized controlled clinical trial
- Compass Pathways previously made major waves when they successfully achieved the primary endpoint for their COMP360 synthetic psilocybin drug in their second Phase III trial
The intrigue:
- AtaiBeckley (NASDAQ: ATAI) is a founding shareholder of Compass Pathways and notably just recently entered into a deal to be acquired by Eli Lilly (NYSE: LLY) for up to $3.8B USD
